Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 1733

1.

Cardiovascular Effects of Glucose-Lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.

Thompson PL, Davis TM.

Clin Ther. 2016 Nov 15. pii: S0149-2918(16)30793-7. doi: 10.1016/j.clinthera.2016.10.008. [Epub ahead of print] Review.

PMID:
27863704
2.

Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines.

Robson A, Sturman J, Williamson P, Conboy P, Penney S, Wood H.

J Laryngol Otol. 2016 May;130(S2):S13-S22.

3.

Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS).

Mondesir FL, Brown TM, Muntner P, Durant RW, Carson AP, Safford MM, Levitan EB.

Am Heart J. 2016 Nov;181:43-51. doi: 10.1016/j.ahj.2016.08.002.

PMID:
27823692
4.
5.

Intermittent hypoxia in obese Zucker rats: cardiometabolic and inflammatory effects.

Briançon-Marjollet A, Monneret D, Henri M, Joyeux-Faure M, Totoson P, Cachot S, Faure P, Godin-Ribuot D.

Exp Physiol. 2016 Nov 1;101(11):1432-1442. doi: 10.1113/EP085783.

PMID:
27615447
6.

JS KSH-JSH-CHL 01-1 CARDIO-METABOLIC RISKS IN HYPERTENSION: ARE WE DIFFERENT FROM WESTERN SOCIETIES?

Itoh H.

J Hypertens. 2016 Sep;34 Suppl 1 - ISH 2016 Abstract Book:e200.

PMID:
27754018
7.

Prevalence of Metabolic Syndrome and its Association with Coronary Artery Disease Among an Urban Elderly South Indian Population (CURES- 145).

Pradeepa R, Surendar J, Indulekha K, Chella S, Anjana RM, Mohan V.

J Assoc Physicians India. 2016 May;64(5):20-25.

PMID:
27735144
8.

Acute hyperglycemia suppresses left ventricular diastolic function and inhibits autophagic flux in mice under prohypertrophic stimulation.

Xie J, Cui K, Hao H, Zhang Y, Lin H, Chen Z, Huang X, Cao S, Liao W, Bin J, Kitakaze M, Liao Y.

Cardiovasc Diabetol. 2016 Sep 22;15(1):136.

9.

Metabolic syndrome in drug naïve patients with substance use disorder.

Bathla M, Singh M, Anjum S, Kulhara P, Jangli S IIIrd.

Diabetes Metab Syndr. 2016 Sep 3. pii: S1871-4021(16)30183-7. doi: 10.1016/j.dsx.2016.08.022. [Epub ahead of print]

PMID:
27618517
10.
11.

Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.

Anderluh M, Kocic G, Tomovic K, Kocic R, Deljanin-Ilic M, Smelcerovic A.

Pharmacol Ther. 2016 Jul 30. pii: S0163-7258(16)30134-6. doi: 10.1016/j.pharmthera.2016.07.009. [Epub ahead of print]

PMID:
27484974
12.

Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators..

Diabetes Care. 2016 Oct;39(10):1684-92. doi: 10.2337/dc16-0798.

PMID:
27465265
13.

Chronic Treatment With an Erythropoietin Receptor Ligand Prevents Chronic Kidney Disease-Induced Enlargement of Myocardial Infarct Size.

Nishizawa K, Yano T, Tanno M, Miki T, Kuno A, Tobisawa T, Ogasawara M, Muratsubaki S, Ohno K, Ishikawa S, Miura T.

Hypertension. 2016 Sep;68(3):697-706. doi: 10.1161/HYPERTENSIONAHA.116.07480.

PMID:
27456523
14.

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.

Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF.

JAMA. 2016 Jul 19;316(3):313-24. doi: 10.1001/jama.2016.9400.

PMID:
27434443
15.

Insulin Postconditioning Reduces Infarct Size in the Porcine Heart in a Dose-Dependent Manner.

Slettom G, Jonassen AK, Dahle GO, Seifert R, Larsen TH, Berge RK, Nordrehaug JE.

J Cardiovasc Pharmacol Ther. 2016 Jul 7. pii: 1074248416657611. [Epub ahead of print]

PMID:
27390144
16.

Inhibition of Soluble Epoxide Hydrolase Limits Mitochondrial Damage and Preserves Function Following Ischemic Injury.

Akhnokh MK, Yang FH, Samokhvalov V, Jamieson KL, Cho WJ, Wagg C, Takawale A, Wang X, Lopaschuk GD, Hammock BD, Kassiri Z, Seubert JM.

Front Pharmacol. 2016 Jun 7;7:133. doi: 10.3389/fphar.2016.00133.

17.

MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: the KORA F4 study.

von Toerne C, Huth C, de Las Heras Gala T, Kronenberg F, Herder C, Koenig W, Meisinger C, Rathmann W, Waldenberger M, Roden M, Peters A, Thorand B, Hauck SM.

Diabetologia. 2016 Sep;59(9):1882-92. doi: 10.1007/s00125-016-4024-2.

PMID:
27344311
18.

Effects of activation of endocannabinoid system on myocardial metabolism.

Polak A, Harasim E, Chabowski A.

Postepy Hig Med Dosw (Online). 2016 May 21;70(0):542-55. doi: 10.5604/17322693.1202483.

19.

Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The British Regional Heart Study.

Wannamethee SG, Welsh P, Lennon L, Papacosta O, Whincup PH, Sattar N.

Diabetologia. 2016 Sep;59(9):1904-12. doi: 10.1007/s00125-016-4011-7.

20.

Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.

Levine MJ.

Curr Diabetes Rev. 2016 Jun 13. [Epub ahead of print]

PMID:
27296042
Items per page

Supplemental Content

Loading ...
Support Center